Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of ABSK021 in Healthy Subjects
NCT05280483Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Plasma Concentration at 4 weeks, Area Under the Concentration-Time Curve from Zero to Infinity at 4 weeks and 2 more. Started Jul 2022; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT05280483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280483.